RARX - Ra Pharmaceuticals, Inc. - SEC Form 4 Insider Trading Screener
21 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2019-11-15 | RARX | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $46.66 | -10,595 | 7,132 | -60% | -$494,319 | |||||
| D | 2019-11-14 | RARX | Read Simon | Chief Scientific Officer | S - Sale+OE | $46.68 | -10,000 | 6,234 | -62% | -$466,808 | |||||
2019-10-17 | RARX | Ricardo Alonso | See Remarks | S - Sale | $46.70 | -2,285 | 6,858 | -25% | -$106,710 | ||||||
| D | 2019-10-16 | RARX | Read Simon | Chief Scientific Officer | S - Sale+OE | $46.87 | -10,000 | 6,234 | -62% | -$468,726 | |||||
| D | 2019-10-15 | RARX | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $46.89 | -10,595 | 7,132 | -60% | -$496,769 | |||||
| D | 2019-09-16 | RARX | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $25.26 | -10,595 | 7,132 | -60% | -$267,675 | |||||
| D | 2019-09-12 | RARX | Read Simon | Chief Scientific Officer | S - Sale+OE | $25.41 | -10,000 | 6,234 | -62% | -$254,050 | |||||
| D | 2019-08-23 | RARX | Read Simon | Chief Scientific Officer | S - Sale+OE | $27.77 | -10,000 | 6,234 | -62% | -$277,703 | |||||
| D | 2019-08-23 | RARX | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $27.77 | -10,595 | 7,132 | -60% | -$294,226 | |||||
2019-08-23 | RARX | Ricardo Alonso | See Remarks | S - Sale | $27.89 | -2,285 | 9,143 | -20% | -$63,740 | ||||||
| D | 2019-07-17 | RARX | Read Simon | Chief Scientific Officer | S - Sale+OE | $32.95 | -10,000 | 6,234 | -62% | -$329,479 | |||||
| D | 2019-07-15 | RARX | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $33.10 | -10,595 | 7,132 | -60% | -$350,647 | |||||
2019-06-21 | RARX | Ricardo Alonso | See Remarks | S - Sale | $23.72 | -2,857 | 11,428 | -20% | -$67,782 | ||||||
| D | 2019-06-18 | RARX | Read Simon | Chief Scientific Officer | S - Sale+OE | $22.25 | -10,000 | 6,234 | -62% | -$222,467 | |||||
| D | 2019-06-17 | RARX | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $21.84 | -10,595 | 7,132 | -60% | -$231,384 | |||||
2018-12-14 | RARX | New Enterprise Associates 13 LP | 10% | P - Purchase | $15.50 | +645,161 | 6,135,234 | +12% | +$9,999,996 | ||||||
2018-12-12 | RARX | Ra Capital Management, LLC | Dir, 10% | P - Purchase | $15.50 | +1,006,452 | 4,858,260 | +26% | +$15,600,006 | ||||||
2018-12-14 | RARX | Shah Rajeev M. | Dir, 10% | P - Purchase | $15.50 | +1,006,452 | 4,858,260 | +26% | +$15,600,006 | ||||||
2018-02-16 | RARX | New Enterprise Associates 13 LP | 10% | P - Purchase | $6.00 | +2,000,000 | 5,490,073 | +57% | +$12,000,000 | ||||||
2018-02-14 | RARX | Shah Rajeev M. | Dir, 10% | P - Purchase | $6.00 | +2,500,000 | 3,851,808 | +185% | +$15,000,000 | ||||||
2018-02-14 | RARX | Ra Capital Management, LLC | Dir, 10% | P - Purchase | $6.00 | +2,500,000 | 3,851,808 | +185% | +$15,000,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |